Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NRIX

Nurix Therapeutics Inc

Dec 12 • 04:00PM ET

20.56

Dollar change -0.75
Percentage change -3.52	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE CRSP BMRN EDIT NTLA CARA BLUE KPTI RGNX PTGX

| Held by: VTI IWM ARKG VXF XBI IBB IWO VTWO SCHA VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.91	Insider Own	2.74%	Shs Outstand	70.84M	Perf Week	2.49%
Market Cap	1.46B	Forward P/E	-	EPS next Y	-2.79	Insider Trans	-5.91%	Shs Float	68.89M	Perf Month	-23.94%
Income	-176.98M	PEG	-	EPS next Q	-0.68	Inst Own	95.14%	Short Float	13.57%	Perf Quarter	-17.10%
Sales	56.42M	P/S	25.81	EPS this Y	-6.18%	Inst Trans	6.07%	Short Ratio	10.46	Perf Half Y	22.89%
Book/sh	5.62	P/B	3.66	EPS next Y	0.71%	ROA	-43.07%	Short Interest	9.35M	Perf Year	148.01%
Cash/sh	6.33	P/C	3.25	EPS next 5Y	-	ROE	-57.96%	52W Range	7.65 - 29.56	Perf YTD	99.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-59.00%	ROI	-44.53%	52W High	-30.45%	Beta	2.12
Dividend TTM	-	Quick Ratio	5.28	Sales past 5Y	38.34%	Gross Margin	71.85%	52W Low	168.76%	ATR (14)	1.52
Dividend Ex-Date	-	Current Ratio	5.28	EPS Y/Y TTM	-5.94%	Oper. Margin	-343.30%	RSI (14)	40.11	Volatility	8.22% 6.75%
Employees	284	Debt/Eq	0.07	Sales Y/Y TTM	-17.76%	Profit Margin	-313.65%	Recom	1.22	Target Price	32.11
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	1.06%	Payout	-	Rel Volume	0.96	Prev Close	21.31
Sales Surprise	-15.93%	EPS Surprise	2.57%	Sales Q/Q	-31.84%	Earnings	Oct 11 AMC	Avg Volume	893.58K	Price	20.56
SMA20	-6.03%	SMA50	-13.21%	SMA200	4.14%	Trades		Volume	859,765	Change	-3.52%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Initiated	BTIG Research	Buy	$35
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$35
Oct-24-24	Initiated	UBS	Buy	$35
Oct-11-24	Initiated	Jefferies	Buy	$41
Sep-06-24	Resumed	Robert W. Baird	Outperform	$26
Jul-31-24	Initiated	Truist	Buy	$36
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Mar-09-23	Initiated	Barclays	Overweight	$20
Feb-28-23	Initiated	Oppenheimer	Outperform	$25
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight	$11
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$25
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$28
Dec-29-21	Initiated	H.C. Wainwright	Buy	$62
Oct-14-21	Initiated	SVB Leerink	Outperform	$50
Jun-04-21	Resumed	Robert W. Baird	Outperform	$45 → $46
Apr-30-21	Resumed	Piper Sandler	Overweight	$60
Apr-30-21	Initiated	RBC Capital Mkts	Outperform	$42
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform	$40
Aug-18-20	Initiated	Stifel	Buy	$34

Show Previous Ratings

Dec-11-24 12:05PM	Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers? (Insider Monkey)
Dec-09-24 06:00PM	Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting (GlobeNewswire) +6.78%
Dec-04-24 01:10PM	Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-02-24 07:00AM	Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-25-24 07:00AM	Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
04:00PM	Loading…
Nov-20-24 04:00PM	Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (GlobeNewswire)
Nov-17-24 10:30AM	Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 (GlobeNewswire)
Nov-05-24 09:00AM	Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-24 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-21-24 04:00PM	Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit (GlobeNewswire)
05:45AM	Nurix Therapeutics NX-5948 shows promise in Waldenstroms macroglobulinaemia trial (Clinical Trials Arena)
Oct-19-24 08:00AM	Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia (GlobeNewswire)
Oct-16-24 04:35PM	Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur (GlobeNewswire)
Oct-11-24 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.10% +6.47%
04:00PM	Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
07:00AM	Loading…
Oct-09-24 07:00AM	Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology (GlobeNewswire)
Sep-30-24 07:00AM	Nurix Therapeutics Announces Presentations at Discovery on Target Conference (GlobeNewswire)
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-06-24 07:00AM	Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit (GlobeNewswire)
Sep-05-24 12:01AM	Nurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-27-24 12:50AM	Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX) (GuruFocus.com)
Jul-25-24 09:55AM	How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27% (Zacks)
Jul-16-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice (Zacks)
Jul-11-24 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.84% +8.13%
04:00PM	Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-08-24 07:00AM	Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day (GlobeNewswire) +5.29%
Jun-20-24 07:02PM	Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX) (GuruFocus.com) +13.72%
05:26PM	Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike (PR Newswire)
05:05AM	Loading…
Jun-19-24 05:05AM	Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains? (Zacks)
Jun-17-24 04:06PM	Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment (Investor's Business Daily) +20.60%
08:45AM	Biotech Stock Nurix Therapeutics Jumps On Positive Leukemia Treatment Trial (Investor's Business Daily)
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-16-24 05:30AM	Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) (GlobeNewswire)
Jun-10-24 07:00AM	Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024) (GlobeNewswire)
May-29-24 07:00AM	Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 07:00AM	Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer (GlobeNewswire)
May-20-24 04:41PM	Nurix Therapeutics Names New Board Chair (MT Newswires)
04:00PM	Nurix Therapeutics Announces Board Chair Transition (GlobeNewswire)
10:21AM	Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last? (Zacks)
May-14-24 10:00AM	Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024) (GlobeNewswire) +7.25%
07:39AM	Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target (MT Newswires)
May-07-24 07:00AM	Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +7.11%
Apr-16-24 06:21PM	Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.24%
Apr-11-24 11:38PM	Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering (GlobeNewswire) +9.69%
04:00PM	Nurix Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Apr-10-24 11:53AM	NRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.24%
09:29AM	Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study (Zacks)
08:31AM	Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024 (GuruFocus.com)
08:10AM	Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-09-24 01:15PM	Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies (GlobeNewswire) +26.67%
07:00AM	Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 (GlobeNewswire)
Apr-03-24 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-02-24 07:00AM	Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences (GlobeNewswire)
Mar-25-24 07:00AM	Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) (GlobeNewswire)
Mar-20-24 09:40AM	Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting (GlobeNewswire)
Mar-11-24 07:00AM	Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial (GlobeNewswire)
Mar-06-24 04:00PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +17.39% -7.41%
Mar-05-24 04:30PM	Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Feb-23-24 06:20AM	Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Feb-16-24 07:04PM	Nurix Therapeutics Inc (NRIX) Reports Robust Year-End Financials and Clinical Progress (GuruFocus.com)
Feb-15-24 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +6.95%
04:00PM	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-01-24 04:01PM	Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader (GlobeNewswire)
10:01AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Jan-16-24 04:01PM	Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL (GlobeNewswire) -6.94%
Jan-08-24 07:00AM	Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases (GlobeNewswire)
Jan-02-24 04:01PM	Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.68%
Dec-21-23 05:01PM	CFO Houte Van Sells 10,906 Shares of Nurix Therapeutics Inc (GuruFocus.com) -6.41%
Dec-13-23 04:32PM	Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of Directors (GlobeNewswire) +6.30%
Dec-11-23 12:00PM	Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-23 04:01PM	Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +8.68%
Nov-07-23 04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.31%
Nov-02-23 09:00AM	Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-23 04:01PM	Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial (GlobeNewswire)
Oct-18-23 09:35AM	Down -34.9% in 4 Weeks, Here's Why Nurix Therapeutics, Inc. (NRIX) Looks Ripe for a Turnaround (Zacks) -13.16%
Oct-14-23 06:01AM	Nurix Therapeutics Inc (NRIX) Reports Q3 Fiscal 2023 Financial Results (GuruFocus.com)
Oct-12-23 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.03%
04:01PM	Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-11-23 07:09AM	Nurix (NRIX) to Report Q3 Earnings: What's in Store? (Zacks)
Oct-05-23 09:35AM	Nurix Therapeutics, Inc. (NRIX) Loses -20.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-04-23 09:35AM	Nurix Therapeutics, Inc. (NRIX) Loses -19.36% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-28-23 10:00AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Sep-20-23 09:30AM	Nurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
Sep-15-23 12:00PM	Nurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 215.32%: Read This Before Placing a Bet (Zacks)
Sep-11-23 12:10PM	Nurix (NRIX) Stock Increases 9% in a Month: Here's Why (Zacks)
Sep-08-23 05:32AM	Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock? (Zacks) +5.23%
Sep-07-23 07:00AM	Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics (GlobeNewswire) +8.32%
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-02-23 05:01AM	Insider Sell: Gwenn Hansen Sells 1,884 Shares of Nurix Therapeutics Inc (GuruFocus.com)
Jul-24-23 09:55AM	Wall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to Trade (Zacks)
Jul-15-23 08:12AM	Nurix Therapeutics Second Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Jul-13-23 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-11-23 10:00AM	Swedish Orphan Biovitrum (BIOVF) Earnings Expected to Grow: Should You Buy? (Zacks)
Jun-29-23 10:00AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ring Christine	Chief Legal Officer	Dec 02 '24	Option Exercise	1.86	5,760	10,714	33,844	Dec 02 06:00 PM
Ring Christine	Chief Legal Officer	Dec 02 '24	Sale	21.73	5,760	125,155	28,084	Dec 02 06:00 PM
CHRISTINE RING	Officer	Dec 02 '24	Proposed Sale	22.11	5,760	127,354		Dec 02 04:36 PM
Ring Christine	Chief Legal Officer	Nov 04 '24	Option Exercise	9.57	3,290	31,485	31,374	Nov 04 05:48 PM
Ring Christine	Chief Legal Officer	Nov 04 '24	Sale	25.00	3,290	82,250	28,084	Nov 04 05:48 PM
CHRISTINE RING	Officer	Nov 04 '24	Proposed Sale	24.47	3,290	80,506		Nov 04 04:29 PM
Ring Christine	Chief Legal Officer	Nov 01 '24	Option Exercise	1.86	5,760	10,714	33,844	Nov 01 05:57 PM
Ring Christine	Chief Legal Officer	Nov 01 '24	Sale	24.28	5,760	139,867	28,084	Nov 01 05:57 PM
van Houte Hans	Chief Financial Officer	Nov 01 '24	Sale	24.28	3,546	86,083	33,724	Nov 01 05:57 PM
JOHANNES VAN HOUTE	Officer	Nov 01 '24	Proposed Sale	24.58	3,546	87,161		Nov 01 04:50 PM
CHRISTINE RING	Officer	Nov 01 '24	Proposed Sale	24.58	5,760	141,581		Nov 01 04:41 PM
van Houte Hans	Chief Financial Officer	Oct 30 '24	Option Exercise	0.00	8,636	0	39,638	Oct 30 08:30 PM
van Houte Hans	Chief Financial Officer	Oct 30 '24	Sale	24.30	2,368	57,554	37,270	Oct 30 08:30 PM
Hansen Gwenn	Chief Scientific Officer	Oct 30 '24	Option Exercise	0.00	8,957	0	54,107	Oct 30 08:30 PM
Hansen Gwenn	Chief Scientific Officer	Oct 30 '24	Sale	24.30	3,437	83,536	50,670	Oct 30 08:30 PM
Ring Christine	Chief Legal Officer	Oct 30 '24	Option Exercise	0.00	7,674	0	32,266	Oct 30 08:30 PM
Ring Christine	Chief Legal Officer	Oct 30 '24	Sale	24.30	4,182	101,644	28,084	Oct 30 08:30 PM
Ring Christine	Chief Legal Officer	Oct 14 '24	Option Exercise	9.57	3,290	31,485	27,882	Oct 15 09:16 AM
Ring Christine	Chief Legal Officer	Oct 14 '24	Sale	25.00	3,290	82,250	24,592	Oct 15 09:16 AM
Ring Christine	Chief Legal Officer	Oct 01 '24	Option Exercise	1.86	5,760	10,714	30,352	Oct 01 07:36 PM
Ring Christine	Chief Legal Officer	Oct 01 '24	Sale	22.23	5,760	128,017	24,592	Oct 01 07:36 PM
CHRISTINE RING	Officer	Oct 01 '24	Proposed Sale	22.47	9,050	203,354		Oct 01 04:32 PM
Ring Christine	Chief Legal Officer	Sep 03 '24	Option Exercise	4.66	9,050	42,199	33,642	Sep 03 05:33 PM
Ring Christine	Chief Legal Officer	Sep 03 '24	Sale	24.94	9,050	225,736	24,592	Sep 03 05:33 PM
CHRISTINE RING	Officer	Sep 03 '24	Proposed Sale	25.20	9,050	228,060		Sep 03 04:28 PM
Ring Christine	Chief Legal Officer	Aug 26 '24	Option Exercise	6.08	9,870	60,046	34,462	Aug 26 06:23 PM
Ring Christine	Chief Legal Officer	Aug 26 '24	Sale	25.01	9,870	246,843	24,592	Aug 26 06:23 PM
van Houte Hans	Chief Financial Officer	Aug 26 '24	Sale	25.22	20,000	504,370	31,002	Aug 26 05:41 PM
JOHANNES VAN HOUTE	Officer	Aug 26 '24	Proposed Sale	24.02	20,000	480,400		Aug 26 04:25 PM
CHRISTINE RING	Officer	Aug 26 '24	Proposed Sale	24.02	9,870	237,077		Aug 26 04:24 PM
van Houte Hans	Chief Financial Officer	Aug 01 '24	Sale	21.45	3,477	74,576	51,002	Aug 01 07:06 PM
Ring Christine	Chief Legal Officer	Aug 01 '24	Option Exercise	1.86	5,760	10,714	30,352	Aug 01 07:06 PM
Ring Christine	Chief Legal Officer	Aug 01 '24	Sale	21.43	5,760	123,459	24,592	Aug 01 07:06 PM
JOHANNES VAN HOUTE	Officer	Aug 01 '24	Proposed Sale	21.88	3,477	76,077		Aug 01 04:31 PM
CHRISTINE RING	Officer	Aug 01 '24	Proposed Sale	21.88	5,760	126,029		Aug 01 04:26 PM
Hansen Gwenn	Chief Scientific Officer	Jul 30 '24	Option Exercise	0.00	8,957	0	48,558	Jul 30 07:06 PM
Hansen Gwenn	Chief Scientific Officer	Jul 30 '24	Sale	20.67	3,408	70,436	45,150	Jul 30 07:06 PM
Ring Christine	Chief Legal Officer	Jul 30 '24	Option Exercise	0.00	7,674	0	27,512	Jul 30 07:06 PM
Ring Christine	Chief Legal Officer	Jul 30 '24	Sale	20.67	2,920	60,350	24,592	Jul 30 07:06 PM
van Houte Hans	Chief Financial Officer	Jul 30 '24	Option Exercise	0.00	8,636	0	56,969	Jul 30 07:06 PM
van Houte Hans	Chief Financial Officer	Jul 30 '24	Sale	20.67	2,490	51,463	54,479	Jul 30 07:06 PM
Ring Christine	Chief Legal Officer	Jul 01 '24	Option Exercise	1.86	5,760	10,714	25,598	Jul 01 06:35 PM
Ring Christine	Chief Legal Officer	Jul 01 '24	Sale	20.81	5,760	119,837	19,838	Jul 01 06:35 PM
van Houte Hans	Chief Financial Officer	Jun 20 '24	Sale	20.01	20,000	400,216	48,333	Jun 20 04:58 PM
Ring Christine	Chief Legal Officer	Jun 13 '24	Option Exercise	1.86	1,864	3,467	21,702	Jun 13 06:39 PM
Ring Christine	Chief Legal Officer	Jun 13 '24	Sale	17.02	1,864	31,721	19,838	Jun 13 06:39 PM
Ring Christine	Chief Legal Officer	Jun 12 '24	Option Exercise	1.86	1,900	3,534	21,738	Jun 12 07:30 PM
Ring Christine	Chief Legal Officer	Jun 12 '24	Sale	17.01	1,900	32,319	19,838	Jun 12 07:30 PM
Ring Christine	Chief Legal Officer	Jun 05 '24	Option Exercise	1.86	400	744	20,238	Jun 05 06:01 PM
Ring Christine	Chief Legal Officer	Jun 05 '24	Sale	17.00	400	6,801	19,838	Jun 05 06:01 PM
Ring Christine	Chief Legal Officer	Jun 03 '24	Option Exercise	1.86	1,596	2,969	21,434	Jun 03 06:36 PM
Ring Christine	Chief Legal Officer	Jun 03 '24	Sale	17.01	1,596	27,153	19,838	Jun 03 06:36 PM
van Houte Hans	Chief Financial Officer	May 02 '24	Sale	12.83	3,499	44,878	68,333	May 02 06:01 PM
van Houte Hans	Chief Financial Officer	Apr 30 '24	Option Exercise	0.00	4,886	0	73,219	Apr 30 06:33 PM
van Houte Hans	Chief Financial Officer	Apr 30 '24	Sale	12.04	1,387	16,703	71,832	Apr 30 06:33 PM
Hansen Gwenn	Chief Scientific Officer	Apr 30 '24	Option Exercise	0.00	5,206	0	41,608	Apr 30 06:33 PM
Hansen Gwenn	Chief Scientific Officer	Apr 30 '24	Sale	12.04	2,007	24,169	39,601	Apr 30 06:33 PM
Ring Christine	Chief Legal Officer	Apr 30 '24	Option Exercise	0.00	3,924	0	21,351	Apr 30 06:33 PM
Ring Christine	Chief Legal Officer	Apr 30 '24	Sale	12.04	1,513	18,220	19,838	Apr 30 06:33 PM
van Houte Hans	Chief Financial Officer	Feb 16 '24	Sale	10.02	6,812	68,223	68,333	Feb 16 07:20 PM
van Houte Hans	Chief Financial Officer	Jan 30 '24	Option Exercise	0.00	4,886	0	76,816	Jan 30 06:53 PM
van Houte Hans	Chief Financial Officer	Jan 30 '24	Sale	7.99	1,671	13,352	75,145	Jan 30 06:53 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '24	Option Exercise	0.00	5,207	0	38,736	Jan 30 06:52 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '24	Sale	7.99	2,334	18,649	36,402	Jan 30 06:52 PM
Ring Christine	Chief Legal Officer	Jan 30 '24	Option Exercise	0.00	3,924	0	19,187	Jan 30 06:52 PM
Ring Christine	Chief Legal Officer	Jan 30 '24	Sale	7.99	1,760	14,063	17,427	Jan 30 06:52 PM
van Houte Hans	Chief Financial Officer	Dec 20 '23	Sale	10.00	3,541	35,421	71,930	Dec 21 05:19 PM
van Houte Hans	Chief Financial Officer	Dec 19 '23	Sale	10.00	10,906	109,093	75,471	Dec 20 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRIX

Nurix Therapeutics Inc

Upgrade your FINVIZ experience